Krystal Biotech
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 229
- Market Cap
- $5.6B
- Website
- http://www.krystalbio.com
- Introduction
Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Clinical Trials
18
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa
- Conditions
- Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis Bullosa
- Interventions
- Biological: KB803Drug: Placebo
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT07016750
- Locations
- 🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis
- Conditions
- Neurotrophic Keratitis
- Interventions
- Biological: KB801Drug: Placebo
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06999733
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸Azul Vision - California Eye Specialists Medical Group Inc., Pasadena, California, United States
🇺🇸Midwest Cornea Associates, Carmel, Indiana, United States
A Study Assessing KB304 for the Treatment of Wrinkles in Women
- Conditions
- Wrinkles in DecolletagePigmentationDécolleté Wrinkles
- Interventions
- Drug: 0.9% Normal Saline (NS)
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT06724900
- Locations
- 🇺🇸
Steve Yoelin Medical Associates, Newport Beach, California, United States
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
- Conditions
- Epidermolysis Bullosa DystrophicaEpidermolysis Bullosa Dystrophica, RecessiveEpidermolysis Bullosa Dystrophica Dominans
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06563414
- Locations
- 🇺🇸
Krystal Biotech, Pittsburgh, Pennsylvania, United States
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- Conditions
- Lung Cancer, Non-small CellLung Cancer MetastaticSolid Tumor, AdultAdvanced CancerLung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06228326
- Locations
- 🇺🇸
XCancer Research Network/Dothan Hematology & Oncology, Dothan, Alabama, United States
🇺🇸BRCR Global, Weston, Florida, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Krystal Biotech Initiates Phase 3 Trial of KB803 Gene Therapy for Corneal Complications in Dystrophic Epidermolysis Bullosa
Krystal Biotech has dosed the first patient in its Phase 3 IOLITE trial evaluating KB803 eye drop gene therapy for treating corneal abrasions in dystrophic epidermolysis bullosa patients.
Repurposing Losartan: Hypertension Drug Shows Promise for Treating Epidermolysis Bullosa in Children
Losartan, a medication long used to treat high blood pressure in adults, has demonstrated promising results in healing lesions associated with epidermolysis bullosa (butterfly skin disease) in children.
FDA Approves Vyjuvek: Breakthrough Topical Gene Therapy for Dystrophic Epidermolysis Bullosa
The FDA has granted approval for Vyjuvek, making it the first-ever topical gene therapy authorized for treating dystrophic epidermolysis bullosa (DEB), a rare genetic condition causing severe skin fragility.
Krystal Biotech and CRISPR Therapeutics Announce Key Updates in Gene Therapy Programs
Krystal Biotech reported a 473% increase in full-year revenue, driven by VYJUVEK sales, and anticipates European and Japanese regulatory decisions in 2025.
EMA Postpones Decision on Krystal Biotech's B-VEC for Dystrophic Epidermolysis Bullosa
The European Medicines Agency (EMA) has delayed its decision on Krystal Biotech's B-VEC (beremagene geperpavec-svdt) for treating dystrophic epidermolysis bullosa (DEB).
FDA Accepts Abeona's BLA Resubmission for Pz-Cel in Recessive Dystrophic Epidermolysis Bullosa
The FDA has accepted Abeona Therapeutics' resubmitted Biologics License Application (BLA) for pz-cel, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).
Krystal Biotech's VYJUVEK Drives Revenue Growth; Expands Pipeline
Krystal Biotech reports $83.8 million in product revenue, driven by VYJUVEK sales following its FDA approval for dystrophic epidermolysis bullosa (DEB).
FDA Approves First Gene Therapy, Vijuvek, for Rare Skin Disease Epidermolysis Bullosa
The FDA has approved Vijuvek, a topical gene therapy developed by Krystal Biotech, as the first treatment of its kind for epidermolysis bullosa (EB).
FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa
The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.